Higher-Risk MDS Satellite Symposium

A real-world population of patients with relapsed/refractory B-cell acute lymphoblastic leukemia are reported to have had a high rate of complete remissions following treatment with brexucabtagene autoleucel.

A recently published article highlights the use of CD4-positive/CD8-positive double-positive T cells as a predictive marker for graft-versus-host disease.

The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.

Findings from the phase 2 MAJIC-PV trial highlight a superior event-free survival and overall survival following ruxolitinib vs best available treatment in patients with polycythemia vera who were intolerant/resistant to hydroxycarbamide.

Lead study author Ruben Mesa, MD, discusses findings from the MOMENTUM trial assessing the use of momelotinib in the treatment of myelofibrosis.